SCHEMBL5446265

SCHEMBL5446265

CN1CCC(Oc2cccc(-c3c(C4CCCCC4)c4ccc(C(=O)O)cc4n3CC(=O)N(C)C)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.40
MMP12 P39900 1/20 0.40
RAB9A P51151 2/20 0.37
CYP2D6 P10635 1/20 0.36
HRH1 P35367 1/20 0.36
KCNH2 Q12809 1/20 0.36
ROCK2 O75116 1/20 0.36
MTHFD1 P11586 1/20 0.36
MTHFD2 P13995 1/20 0.36
AVPR1B P47901 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
SLC16A3 O15427 2/20 0.35
SLC16A1 P53985 2/20 0.35
ESR1 P03372 1/20 0.35
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
SCN1A P35498 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN3A Q9NY46 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14468740 0.92 PRKCA (0.39) PRKCAMMP12RAB9AROCK2MTHFD1
SCHEMBL5433781 0.88 PRKCA (0.43) PRKCAMMP12MAPT
SCHEMBL2907228 0.84 PRKCA (0.50) PRKCAMMP12CYP2D6HRH1KCNH2
SCHEMBL5433680 0.84 PRKCA (0.45) PRKCAMMP12MAPT
SCHEMBL5442625 0.84 PRKCA (0.45) PRKCAMMP12MAPT
SCHEMBL5436409 0.83 PRKCA (0.44) PRKCAMMP12MAPT
SCHEMBL5436038 0.83 PRKCA (0.44) PRKCAMMP12CYP2D6HRH1KCNH2
SCHEMBL5444140 0.81 PRKCA (0.45) PRKCAMMP12AVPR1BMAPT
SCHEMBL5402086 0.81 PRKCA (0.47) PRKCAMMP12KMT2AMEN1ADORA2A
SCHEMBL5438018 0.81 PRKCA (0.46) PRKCAMMP12CYP2D6HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US claimed
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) 2007-07-19 US disclosed
EP-1613634-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2006-01-11 EP disclosed
WO-2004087714-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167447-A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase IDO1, NAT1, AANAT PRKCA 4676/4885MMP12 3218/4885RAB9A 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.